Mucopolysaccharidosis Type VI - 11 Studies Found

Recruiting : Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome
: Maroteaux-Lamy Syndrome
: 2014-06-03
: Drug: Naglazyme® 1 mg per kg of body weight administered once weekly as an intravenous infusion
Completed : Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
: Mucopolysaccharidosis VI
: 2002-11-04
: Drug: N-acetylgalactosamine 4-sulfatase
Completed : Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI
: Mucopolysaccharidosis VI
: 2002-11-06
: Drug: N-acetylgalactosamine 4-sulfatase
Completed : A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
:
  • Mucopolysaccharidosis VI
  • Maroteaux-Lamy S
    : 2006-03-02
    : Drug: Naglazyme Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chl
Completed : Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI
: Mucopolysaccharidosis VI
: 2003-08-20
:
  • Drug: Placebo
  • Drug: N-acetylgalactosamine

Completed : Observational Study of Patients With Mucopolysaccharidosis (MPS) VI Who Previously Participated in ASB-00-02
: MPS VI
: 2011-06-29
Active, not recruiting : Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
:
  • MPS I
  • MPS II
  • MPS VI
  • : 2012-04-25
Recruiting : Biomarker for Sly Disease
:
  • Mucopolysaccharidosis VII
  • Sly Disease : 2014-10-23
Completed : A Phase 3 Study of UX003 rhGUS Enzyme Replacement Therapy in Patients With MPS 7
:
  • MPS 7
  • Sly Syndrome
  • : 2014-08-22
    :
    • Drug: UX003 UX003 is a sterile
Active, not recruiting : A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
:
  • Sly Syndrome
  • MPS VII
  • : 2015-04-22
    : Drug: UX003 UX003 is a sterile liquid buffered saline formulation of rhGUS that contains enzyme at a con
Next >>>